Glucagon Receptor

GCGR

Glucagon receptor is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Glucagon Receptor Inhibitors, Agonists, Antagonists & Modulators

Adomeglivant
(LY2409021)

Cat. No.: HY-19904

Adomeglivant (LY2409021) is a potent, selective **glucagon receptor (GluR)** allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus.



Purity: 98.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Albiglutide TFA

Cat. No.: HY-108795A

Albiglutide TFA, a glucagon-like peptide (GLP)-1 mimetic, is a long acting **GLP-1 receptor** agonist for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide TFA is generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human albumin.

HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH_2 (TFA salt)

Purity: 97.51%
Clinical Data: Launched
Size: 1 mg, 5 mg

Avexitide
(Exendin (9-39))

Cat. No.: HY-P0264

Avexitide (Exendin (9-39)) is a specific and competitive **GLP-1** receptor antagonist.

DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH_2

Purity: 99.70%
Clinical Data: Phase 2
Size: 500 μg, 1 mg, 5 mg

Bay 55-9837

Cat. No.: HY-P1160

Bay 55-9837 is a potent and highly selective agonist of **VPAC2**, with a K_d of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.

HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay 55-9837 TFA

Cat. No.: HY-P1160A

Bay 55-9837 TFA is a potent and highly selective agonist of **VPAC2**, with a K_d of 0.65 nM. Bay 55-9837 TFA may be a useful therapy for the research of type 2 diabetes.

HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY-NH_2 (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BETP

Cat. No.: HY-103546

BETP is an agonist of **glucagon-like peptide-1 (GLP-1) receptor**, with EC_{50}s of 0.66 and 0.755 μM for human and rat **GLP-1 receptor**, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cochinchinenin C

Cat. No.: HY-N2452

Cochinchinenin C is a nonpolypeptide agonist of **glucagon-like peptide-1 (GLP-1) receptor**. Cochinchinenin C can be used for the research of diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cotadutide acetate
(MEDI0382 acetate)

Cat. No.: HY-P2231A

Cotadutide acetate (MEDI0382 acetate) is a potent peptide dual agonist of **glucagon-like peptide-1 (GLP-1)** and glucagon receptor with EC_{50} values of 6.9 pM and 10.2 pM, respectively.

1'-(palmitoyl-Glu);
HSQGTFTSDKSEYLDSERARDFVAWLEAGG
(Amide bridge: Glu1'-Lys10) (acetate salt)

Purity: 98.01%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Dapiglutide
(ZP7570)

Cat. No.: HY-P3291

Dapiglutide (ZP7570) is a long-acting **glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R)** dual agonist. Dapiglutide can be used for short bowel syndrome (SBS) research.

Dapiglutide

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ecnoglutide

Cat. No.: HY-P3366

Ecnoglutide is a glucagon-like peptide 1 **(GLP-1) receptor** agonist.

Ecnoglutide

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Exendin (5-39)

Cat. No.: HY-P2497

Exendin (5-39) is a potent glucagon-like peptide 1 (**GLP-1**) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Exendin-3/4 (59-86)

Cat. No.: HY-P1223

Exendin-3/4 (59-86) is a Exendin-4 peptide derivative.

Purity: 97.75%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Exendin-4

(Exenatide)

Cat. No.: HY-13443

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an IC_{50} of 3.22 nM.

Purity: 99.98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

Exendin-4 acetate

(Exenatide acetate)

Cat. No.: HY-13443A

Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting **glucagon-like** peptide-1 receptor agonist with an IC_{50} of 3.22 nM.



Purity: 99.44%
Clinical Data: Phase 4
Size: 1 mg, 5 mg, 10 mg, 25 mg

FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1229

FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

GLP-1 moiety from Dulaglutide

Cat. No.: HY-P1348

GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.

Purity: 95.81%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 2

Cat. No.: HY-112679

GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor **(GLP-1R)** agonist.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GLP-1 receptor agonist 3

Cat. No.: HY-129656

GLP-1 receptor agonist 3 is a **GLP-1 receptor** agonist extracted from patent WO2018109607A1, Example 4A-1, has EC_{50}s of 1.1 nM and 13 nM in Clone H6 and Clone C6 cell lines assay, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 4

Cat. No.: HY-129657

GLP-1 receptor agonist 4 is a **glucagon-like peptide-1 receptor (GLP-1R)** agonist extracted from patent WO2009111700A2, compound 87, has an EC_{50} of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 7

Cat. No.: HY-145412

GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (**GLP-1**). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 8

Cat. No.: HY-138996

GLP-1 receptor agonist 8 is a potent agonist of **GLP-1 R**. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1 receptor agonist 9

Cat. No.: HY-145458

GLP-1 receptor agonist 9 is a **GLP-1 receptor** agonist, example 7, extracted from WO2020234726 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(28-36)amide

Cat. No.: HY-P3101

GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT).



Purity: 96.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GLP-1(28-36)amide TFA

Cat. No.: HY-P3101A

GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(32-36)amide

Cat. No.: HY-P3102

GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GLP-1(32-36)amide TFA

Cat. No.: HY-P3102A

GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(7-36), amide (Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide)

Cat. No.: HY-P0054A

GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(7-36), amide acetate (Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; ...)

Cat. No.: HY-P0054

GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

GLP-1(7-36), amide TFA (Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA)

Cat. No.: HY-P0054B

GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg, 10 mg

GLP-1(7-37)

Cat. No.: HY-P0055

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-1(7-37) acetate

Cat. No.: HY-P0055A

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

GLP-1(9-36)amide

Cat. No.: HY-P1141

GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic **GLP-1 receptor**.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1(9-36)amide TFA

Cat. No.: HY-P1141A

GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic **GLP-1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 1

Cat. No.: HY-144033

GLP-1R agonist 1 is a potent agonist of **GLP-1R**. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 3

Cat. No.: HY-144034

GLP-1R agonist 3 is a potent agonist of **GLP-1R**. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 4

Cat. No.: HY-144035

GLP-1R agonist 4 is a potent agonist of **GLP-1R**. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 5

Cat. No.: HY-144133

GLP-1R agonist 5 is a potent **GLP-1R** agonist with an EC_{50} of <10 nM (WO2021259309A1, compound 35).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 6

Cat. No.: HY-144134

GLP-1R agonist 6 is a potent **GLP-1R** agonist with an EC_{50} of 0.15 nM for human GLP-1R (WO2021249492A1, compound 005A or 005B).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 7

Cat. No.: HY-144135

GLP-1R agonist 7 is a potent **GLP-1R** agonist with an EC_{50} of 0.67 μM (WO2021244645A1, compound WXA001).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R agonist 8

Cat. No.: HY-144136

GLP-1R agonist 8 is a potent **GLP-1R** agonist with an EC_{50} of < 2 nM (WO2021219019A1, compound 129a).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R Antagonist 1

Cat. No.: HY-101116

GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of **glucagon-like peptide 1 receptor (GLP-1R)**, with an IC_{50} of 650 nM.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GLP-1R modulator C16

Cat. No.: HY-141839

GLP-1R modulator C16 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC_{50} 8.43 ± 3.82 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R modulator C5

Cat. No.: HY-141840

GLP-1R modulator C5 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC_{50} 1.59 ± 0.53 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-1R modulator L7-028

Cat. No.: HY-141842

GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC_{50} 11.01 ± 2.73 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GLP-2(1-33)(human)

(GLP-2 (human); Glucagon-like peptide 2 (human))

Cat. No.: HY-P1024

GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the **GLP-2 receptor** and stimulate the growth of intestinal epithelium.

Purity: 99.18%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

GLP-2(3-33)

Cat. No.: HY-P2625

GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on **GLP-2 receptor** (EC_{50}=5.8 nM).

Purity: 99.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon (1-29), bovine, human, porcine

(Porcine glucagon)

Cat. No.: HY-P0082

Glucagon (1-29), bovine, human, porcine is a peptide hormone, produced by pancreatic α-cells. Glucagon stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine activates HNF4α and increases HNF4α phosphorylation.

Purity: 99.81%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Glucagon (1-29), bovine, human, porcine hydrochloride

(Porcine glucagon hydrochloride)

Cat. No.: HY-P0082A

Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glucagon (19-29), human

Cat. No.: HY-P0150

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Glucagon receptor antagonists-1

Cat. No.: HY-10036

Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Glucagon receptor antagonists-2

Cat. No.: HY-50158

Glucagon receptor antagonists-2 is a highly potent glucagon receptor antagonist.



relative stereochemistry

Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glucagon receptor antagonists-3

Cat. No.: HY-50159

Glucagon receptor antagonists-3 is a highly potent glucagon receptor antagonist.



relative stereochemistry

Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glucagon receptor antagonists-5

Cat. No.: HY-128781

Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based **glucagon receptor** antagonist (K_i=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon-like peptide 1 (1-37), human

(HuGLP-1)

Cat. No.: HY-P1145

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the **GLP-1 receptor**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glucagon-like peptide 1 (1-37), human TFA

(HuGLP-1 TFA)

Cat. No.: HY-P1145A

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the **GLP-1 receptor**.

Purity: 97.18%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

GPCR modulator-1

Cat. No.: HY-124803

GPCR modulator-1 is a negative allosteric modulator of **GLP** receptor. GPCR modulator-1 has the potential for type 2 diabetes research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GRA Ex-25

Cat. No.: HY-50675

GRA Ex-25 is an inhibitor of **glucagon receptor**, with IC_{50} of 56 and 55 nM for rat and human glucagon receptors, respectively.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS

Cat. No.: HY-P1231

GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS is an Exendin-4 peptide derivative.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFT

Cat. No.: HY-P1228

HAEGTFT is the first N-terminal 1-7 residues of GLP-1 peptide.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSD

Cat. No.: HY-P1226

HAEGTFTSD is a 9-residue peptide of human GLP-1 peptide or GLP-1(7-36), amide (HY-P0054A). GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretionin a glucose-dependant manner.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

HAEGTFTSDVS

Cat. No.: HY-P1224

HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.

HAEGTFTSDVS

Purity: 98.31%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

L-168049

Cat. No.: HY-103547

L-168049 is a potent, selective, orally active and non-competitive **glucagon receptor** antagonist with IC_{50}s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

LGD-6972

Cat. No.: HY-12525

LGD-6972 is a selective and orally active **glucagon receptor** antagonist. LGD-6972 has the potential for type 2 diabetes research.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Liraglutide

Cat. No.: HY-P0014

Liraglutide is a **glucagon-like peptide-1** (**GLP-1**) receptor agonist used clinically to treat type 2 diabetes mellitus.



Purity: 99.68%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Lixisenatide

Cat. No.: HY-P0119

Lixisenatide is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 2 mg, 5 mg, 10 mg

Lixisenatide acetate

Cat. No.: HY-P0119A

Lixisenatide acetate is a **glucagon-like peptide-1 (GLP-1) receptor** agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).



Purity: 98.53%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

LSN3318839

Cat. No.: HY-142162

LSN3318839 is an orally efficacious positive allosteric modulator of the **glucagon-like peptide-1 receptor (GLP-1R)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY3502970

(GLP-1 receptor agonist 1)

Cat. No.: HY-112185

LY3502970 (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK 0893

Cat. No.: HY-50663

MK 0893 is a potent and selective **glucagon receptor** antagonist with an IC_{50} of 6.6 nM.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Neuropeptide Y, porcine

Cat. No.: HY-P0212

Neuropeptide Y, porcine, a peptide in porcine brain, is capable of inhibiting secretin-stimulated pancreatic secretion.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

NNC-0640

Cat. No.: HY-124622

NNC-0640 is a potent **human G-protein-coupled glucagon receptor (GCGR)** negative allosteric modulator (NAM) with an IC_{50} of 69.2 nM.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oxyntomodulin

Cat. No.: HY-P1144

Oxyntomodulin, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.

HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA

Purity: 98.00%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Oxyntomodulin TFA

Cat. No.: HY-P1144A

Oxyntomodulin TFA, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.

HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06291874

(Glucagon receptor antagonists-4)

Cat. No.: HY-19947

PF-06291874 is a highly potent, non-peptide and orally active **glucagon receptor** antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).



Purity: 99.49%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Secretin (33-59), rat

(Secretin (rat))

Cat. No.: HY-P1244

Secretin (33-59), rat is a 27-aa peptide, acts on **secretin receptor**, enhances the secretion of bicarbonate, enzymes, and K^+ from the pancreas.

HSDGTFTSELSRLQDSARLQRLLQGLV-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Secretin (33-59), rat TFA

(Secretin (rat) (TFA))

Cat. No.: HY-P1244A

Secretin (33-59), rat (TFA) is a 27-aa peptide, which acts on **secretin receptor**, and enhances the secretion of bicarbonate, enzymes, and K^+ from the pancreas.

HSDGTFTSELSRLQDSARLQRLLQGLV-NH_2 (TFA salt)

Purity: 96.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Semaglutide

Cat. No.: HY-114118

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

Semaglutide

Purity: 99.84%
Clinical Data: Launched
Size: 500 µg, 1 mg, 5 mg, 10 mg, 25 mg

Semaglutide TFA

Cat. No.: HY-114118A

Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 **(GLP-1)** receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.

Semaglutide (TFA salt)

Purity: 99.90%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg

Shanzhiside methyl ester

Cat. No.: HY-N0630

Shanzhiside methy lester is isolated from L. rotata. Shanzhiside methyl ester is a small molecule **glucagon-like peptide-1 (GLP-1) receptor** agonist and has the ability to induce anti-allodynic tolerance.



Purity: 98.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Taspoglutide

(ITM077; R1583; BIM51077)

Cat. No.: HY-P0165

Taspoglutide is a long-acting glucagon-like peptide 1 (**GLP-1**) receptor agonist developed for treatment of type 2 diabetes, with an EC_{50} value of 0.06 nM.

H-(Aib)-EGTFTSDVSSYLEGQAAKEFIAWLVK-(Aib)-R-NH_2

Purity: 98.21%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg

Tirzepatide
(LY3298176) Cat. No.: HY-P1731

Tirzepatide (LY3298176) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Tirzepatide hydrochloride
(LY3298176 hydrochloride) Cat. No.: HY-P1731B

Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: 99.82%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tirzepatide TFA
(LY3298176 TFA) Cat. No.: HY-P1731A

Tirzepatide TFA (LY3298176 TFA) is a dual **glucose-dependent insulinotropic polypeptide (GIP)** and **glucagon-like peptide-1 (GLP-1) receptor** agonist that is being developed for the treatment of type 2 diabetes.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

TT-OAD2
Cat. No.: HY-129658A

TT-OAD2 is a non-peptide **glucagon-like peptide-1 (GLP-1) receptor** agonist with an EC_{50} of 5 nM. TT-OAD2 has the potential for diabetes treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TT-OAD2 free base
Cat. No.: HY-129658

TT-OAD2 free base is a non-peptide **glucagon-like peptide-1 (GLP-1) receptor** agonist with an EC_{50} of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Utreglutide
Cat. No.: HY-P3388

Utreglutide is a potent **glucagon-like peptide 1 (GLP-1) receptor** agonit.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

V-0219
Cat. No.: HY-143312

V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the **glucagon-like peptide-1 receptor (GLP-1R)**. V-0219 can be used for obesity-associated diabetes research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0453379
Cat. No.: HY-116819

VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of **glucagon-like peptide-1R (GLP-1R)** with an EC_{50} of 1.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-His1,Glu9]-Glucagon amide
Cat. No.: HY-P1143

[Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the **glucagon receptor**, with a pA_2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes.

SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH_2

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[Des-His1,Glu9]-Glucagon amide TFA
Cat. No.: HY-P1143A

[Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the **glucagon receptor**, with a pA_2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes.

SQGTFTSEYSKYLDSRRAQDFVQWLMNT-NH_2 (TFA salt)

Purity: 98.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

{Val1}-Exendin-3/4

Cat. No.: HY-P1225

{Val1}-Exendin-3/4 is the first N-terminal 1-28 residues of Exendin-4 peptide.

Purity: 99.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg